Analysts expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post $3.50 million in sales for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $9.50 million and the lowest estimate coming in at $500,000.00. Crispr Therapeutics reported sales of $2.39 million during the same quarter last year, which would suggest a positive year over year growth rate of 46.4%. The business is scheduled to issue its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Crispr Therapeutics will report full year sales of $9.10 million for the current year, with estimates ranging from $3.40 million to $23.20 million. For the next year, analysts anticipate that the business will report sales of $34.78 million, with estimates ranging from $8.00 million to $91.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, August 8th. The company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.19). The firm had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $1.47 million. Crispr Therapeutics had a negative net margin of 245.57% and a negative return on equity of 39.58%.
A number of research analysts have recently commented on CRSP shares. Chardan Capital restated a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research note on Wednesday, August 8th. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research note on Monday, September 17th. Zacks Investment Research upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, September 12th. BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Finally, Guggenheim started coverage on Crispr Therapeutics in a research note on Tuesday, October 9th. They issued a “neutral” rating for the company. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $62.47.
Shares of CRSP traded down $1.16 on Tuesday, reaching $36.04. The stock had a trading volume of 615,156 shares, compared to its average volume of 1,408,876. The stock has a market cap of $1.70 billion, a PE ratio of -21.08 and a beta of 3.67. Crispr Therapeutics has a 12-month low of $16.51 and a 12-month high of $73.90.
A number of large investors have recently made changes to their positions in the business. Federated Investors Inc. PA purchased a new position in Crispr Therapeutics during the second quarter valued at $37,101,000. BlackRock Inc. raised its stake in Crispr Therapeutics by 3.7% during the second quarter. BlackRock Inc. now owns 593,527 shares of the company’s stock valued at $34,876,000 after buying an additional 21,309 shares during the last quarter. Orbimed Advisors LLC raised its stake in Crispr Therapeutics by 375.3% during the second quarter. Orbimed Advisors LLC now owns 496,200 shares of the company’s stock valued at $29,157,000 after buying an additional 391,799 shares during the last quarter. ARK Investment Management LLC raised its stake in Crispr Therapeutics by 544.0% during the second quarter. ARK Investment Management LLC now owns 467,140 shares of the company’s stock valued at $27,449,000 after buying an additional 394,606 shares during the last quarter. Finally, Casdin Capital LLC raised its stake in Crispr Therapeutics by 63.0% during the second quarter. Casdin Capital LLC now owns 220,000 shares of the company’s stock valued at $12,927,000 after buying an additional 85,000 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Featured Article: Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.